Hormone Molecular Biology and Clinical Investigation

Editor-in-Chief: Gérard S. Chetrite
Editorial Board: Michael N. Alexis , Aria Baniahmad , Miguel Beato , Roger Bouillon , Angela Brodie , Giuseppe Carruba , Shiuan Chen , John A. Cidlowski , Robert Clarke , Herjan J.T. Coelingh Bennink , Philippa D. Darbre , Jacques Drouin , Maria L. Dufau , Dean P. Edwards , Charles N. Falany , Leandro Fernandez-Perez , Clotilde Ferroud , Bruno Feve , Amilcar Flores-Morales , Michelle T. Foster , Luis M. Garcia-Segura , Amalia Gastaldelli , Julia M.W. Gee , Andrea R. Genazzani , Geoffrey L. Greene , Bernd Groner , Richard Hampl , Leena Hilakivi-Clarke , Michael Hubalek , Hirotaka Iwase , V. Craig Jordan , Helmut Klocker , Ronald Kloet , Fernand Labrie , Carole R. Mendelson , Alfred O. Mück , Alejandro F. Nicola , Bert W. O'Malley , Jean-Pierre Raynaud , Xiangyan Ruan , Jose Russo , Farid Saad , Edwin R. Sanchez , Andrew V. Schally , Roxana Schillaci , Adolf E. Schindler , Gunnar Söderqvist , Valerie Speirs , Frank Z. Stanczyk , Luboslav Starka , Thomas R. Sutter , Jesús A. Tresguerres , Walter Wahli , Ludwig Wildt , Kaiping Yang and Qi Yu

Language: English

First published: March 27, 2010

View latest issue

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

About this journal

Objective
Hormone Molecular Biology and Clinical Investigation (HMBCI) is dedicated to the provision of basic data on molecular aspects of hormones in physiology and pathophysiology. The journal covers the treatment of major diseases, such as endocrine cancers (breast, prostate, endometrium, ovary), renal and lymphoid carcinoma, hypertension, cardiovascular systems, osteoporosis, hormone deficiency in menopause and andropause, obesity, diabetes, brain and related diseases, metabolic syndrome, sexual dysfunction, fetal and pregnancy diseases, as well as the treatment of dysfunctions and deficiencies. HMBCI covers new data on the different steps and factors involved in the mechanism of hormone action. It will equally examine the relation of hormones with the immune system and its environment, as well as new developments in hormone measurements.

Starting 2025, the journal will be transferred to Diamond Open Access on a year-by-year basis. All articles will thus immediately appear under the Creative Commons license CC-BY. There will be no publication costs for the authors. The Open Access transformation is based on Subscribe-to-Open, an alternative model that enables the full Open Access transformation of journals through the continuation of existing subscriptions. The prerequisite for successful transformation is that subscriptions are continued to the same extent as before. The editors of HMBCI and the publisher De Gruyter would therefore like to thank all subscribers for their support, to make the transformation to Open Access possible.

HMBCI is a single-anonymized peer reviewed journal that publishes Original articles, Reviews, Mini Reviews, Short Communications, Case Reports, Letters to the Editor and Opinion papers in in English language. Ahead-of-print publishing ensures faster processing of fully proof-read, DOI-citable articles.

Topics

The superfamily of receptors of the different hormones (steroids, polypeptides and related hormones), and co-regulators (activators and repressors);
Hormones related to the function of growth factors, oncogenes, and cytokines, in normal and neoplastic tissues;
Enzymes and anti-enzymes involved in the formation and disposition of various hormones in connection with the diseases stated above;
Hormone signaling and response to hormone therapy;
Mechanism of cancer cell proliferation under endocrine therapy;
Resistance to hormone therapy and its mechanism;
Hormones and the brain and other neuroendocrine organs;
Hormone replacement therapy;
Pre-clinical studies to test new molecules in isolated models and in human trials;
Hormones and the immune system;
Hormones and the environment;
Initiation and evolution of diseases related to the mechanism of action of hormones;
Therapeutic effect of hormones with regard to the method of administration.

Article formats

Original articles, Reviews, Mini Reviews, Short Communications, Case Reports, Letters to the Editor and Opinion papers

Your Benefits

Most recent research on urgent health issues related to hormones
Thorough selection of top articles within particular fields
Internationally recognized editorial board boosting the prestige of articles
Quick access to issues thanks to ahead of print publishing

Open Access
HbA1C, an overview and suggested formulas for the estimation of average plasma glucose from HBA1C

December 16, 2025

Janan Qassim Muhildeen Al-Khayat, Muhammad Janan Qassim

Download PDF

Introduction The measurement of HbA1c plays an important role in managing Diabetes mellitus [DM] types 1 and 2. It gives the patient a further insight on diabetes control. In addition to the daily blood sugar tests that show the real-time glucose levels, HbA1c gives an insight on the long-term glucose control. Hence the patient realizes that the higher the blood glucose levels over time, the more HbA1c is formed. The formulas to convert HbA1c into an estimated Average Glucose [eAG] are many, complex and may not be memorized by the patients and investigators alike. They may not give comparable results as well. That may create difficulties when they are utilized in diabetes researches. Content Hence the authors have analysed six established formulas and were able to derive three simplified formulas, to help patients and doctors alike easily convert their HbA1c to eAG. The authors tried several mathematical calculations and attempts over the simplest formulas [but with a com- parable result] in order to reach to the desired formulas. Summary The authors suggested 3 formulas that showed around 5 % deviation from the standard formulas results. Outlook The suggested formulas could convert HbA1c into an [eAG] more easily than the standard formulas and make the sugar measurement easier for the patients, health care providers and investigators as well. The suggested formulas would address a real-life need which is patient understanding and simplification of diabetes management favourably.
Open Access
Investigating the association between creatinine-adjusted urinary catecholamines and site-specific bone mineral density in older adults

December 4, 2025

Laith Ashour, Shahed Hammad, Randa Shahwan, Rashed Musamih, Omer Aziziye, Mohammad Zaita, Qusai Aref Fraihat, Ali Schumannalkhtib, Mohammad Al Khreisha, Hani Barakat, Mohammad Sawalmeh

Download PDF

Objectives Osteoporosis is common among older adults, but the relationship between neuroendocrine factors – particularly catecholamines – and bone mineral density (BMD) is not well understood. This study examined associations between catecholamine levels and BMD in older adults. Methods Data from the 2017–2022 biomarkers wave of the Midlife in the United States (MIDUS 3) study were analyzed. Multiple linear regressions assessed associations between creatinine-adjusted urinary norepinephrine and epinephrine levels and BMD at the lumbar spine (L1–L4), right and left total femur, and one-third radius. Models adjusted for age, sex, body mass index (BMI), smoking history, diet, medications (thiazide diuretics, phosphate binders, beta blockers, and vitamin D analogues), and serum creatinine. Results Among 324 participants (41 % male; mean age 64.3±9.3 years), higher epinephrine levels were significantly associated with lower lumbar spine BMD (Beta=−0.122; 95 % CI: [−0.242 to −0.003], p=0.045), while norepinephrine showed no association (p=0.865). No significant relationships were observed at femoral or radial sites, though norepinephrine was marginally linked to lower one-third radius BMD (Beta=−0.087; 95 % CI: [−0.176 to 0.002], p=0.055). Male sex and higher BMI predicted greater BMD (p<0.05), whereas older age was linked to lower femoral and radial BMD (p<0.05). Conclusions Elevated epinephrine levels are associated with reduced lumbar spine BMD in older adults, and elevated norepinephrine levels are associated with reduced distal radius BMD, suggesting catecholamines may influence bone metabolism in a site-specific manner relevant to osteoporosis pathophysiology.

Journal Impact Factor	1.3	2024, Journal Citation Reports (Clarivate, 2025)
5-year Journal Impact Factor	1.5	2024, Journal Citation Reports (Clarivate, 2025)
Journal Citation Indicator	0.2	2024, Journal Citation Reports (Clarivate, 2025)
CiteScore	2.9	2024, Scopus (Elsevier B.V., 2025)
SCImago Journal Rank	0.399	2024, SJR (Scimago Lab, 2025; Data Source: Scopus)
Source Normalized Impact per Paper	0.469	2024, CWTS Journal Indicators (CWTS B.V., 2025; Data Source: Scopus)

Hormone Molecular Biology and Clinical Investigation

Overview

About this journal

Your Benefits

Ahead of Publication / Just Accepted

Issues

Ranking

Submit

Editorial

Abstracting and Indexing

Supplementary Materials

Supplementary Materials

Topics

Topics

External Links

Bibliographic data